1. |
郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析. 中华肿瘤杂志, 2019, 41(1): 19-28.
|
2. |
Bajic P, Van Kuiken ME, Burge BK, et al. Male bladder microbiome relates to lower urinary tract symptoms. Eur Urol Focus, 2020, 6(2): 376-382.
|
3. |
Janssen DAW. The microbiome: another dimension in the pathophysiology of urogenital disease. Eur Urol, 2019, 75(4): 647-648.
|
4. |
Markowski MC, Boorjian SA, Burton JP, et al. The microbiome and genitourinary cancer: a collaborative review. Eur Urol, 2019, 75(4): 637-646.
|
5. |
曾嘉荣. 泌尿道菌群在膀胱癌诊断以及预后判断中的价值研究. 广州: 南方医科大学, 2020: 1-69.
|
6. |
Lotan Y, Black PC, Caba L, et al. Optimal trial design for studying urinary markers in bladder cancer: a collaborative review. Eur Urol Oncol, 2018, 1(3): 223-230.
|
7. |
Cai S, Kandasamy M, Rahmat JN, et al. Lactobacillus rhamnosus GG activation of dendritic cells and neutrophils depends on the dose and time of exposure. J Immunol Res, 2016, 2016: 7402760.
|
8. |
van Puffelen JH, Keating ST, Oosterwijk E, et al. Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. Nat Rev Urol, 2020, 17(9): 513-525.
|
9. |
Helmink BA, Khan MAW, Hermann A, et al. The microbiome, cancer, and cancer therapy. Nat Med, 2019, 25(3): 377-388.
|
10. |
Mbanefo EC, Fu CL, Ho CP, et al. Interleukin-4 signaling plays a major role in urogenital schistosomiasis-associated bladder pathogenesis. Infect Immun, 2020, 88(3): e00669-19.
|
11. |
Dematei A, Fernandes R, Soares R, et al. Angiogenesis in Schistosoma haematobium-associated urinary bladder cancer. APMIS, 2017, 125(12): 1056-1062.
|
12. |
Adebayo AS, Suryavanshi MV, Bhute S, et al. The microbiome in urogenital schistosomiasis and induced bladder pathologies. PLoS Negl Trop Dis, 2017, 11(8): e0005826.
|
13. |
Mostafa MH, Sheweita SA, O’Connor PJ. Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev, 1999, 12(1): 97-111.
|
14. |
Adebayo AS, Mundhe SD, Awobode HO, et al. Metabolite profiling for biomarkers in Schistosoma haematobium infection and associated bladder pathologies. PLoS Negl Trop Dis, 2018, 12(4): e0006452.
|
15. |
Xu W, Yang L, Lee P, et al. Mini-review: perspective of the microbiome in the pathogenesis of urothelial carcinoma. Am J Clin Exp Urol, 2014, 2(1): 57-61.
|
16. |
Bučević Popović V, Šitum M, Chow CT, et al. The urinary microbiome associated with bladder cancer. Sci Rep, 2018, 8(1): 12157.
|
17. |
Chipollini J, Wright JR, Nwanosike H, et al. Characterization of urinary microbiome in patients with bladder cancer: results from a single-institution, feasibility study. Urol Oncol, 2020, 38(7): 615-621.
|
18. |
Mansour B, Monyók Á, Makra N, et al. Bladder cancer-related microbiota: examining differences in urine and tissue samples. Sci Rep, 2020, 10(1): 11042.
|
19. |
Pederzoli F, Ferrarese R, Amato V, et al. Sex-specific alterations in the urinary and tissue microbiome in therapy-naïve urothelial bladder cancer patients. Eur Urol Oncol, 2020, 3(6): 784-788.
|
20. |
张桂豪, 陈嘉炜, 陈杨, 等. 男性非肌层浸润性膀胱癌患者的尿液菌群特征. 中华泌尿外科杂志, 2018, 39(9): 685-689.
|
21. |
Lughezzani G, Sun M, Shariat SF, et al. A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer. Cancer, 2011, 117(1): 103-109.
|
22. |
Wu P, Zhang G, Zhao J, et al. Profiling the urinary microbiota in male patients with bladder cancer in China. Front Cell Infect Microbiol, 2018, 8: 167.
|
23. |
Oresta B, Braga D, Lazzeri M, et al. The microbiome of catheter collected urine in males with bladder cancer according to disease stage. J Urol, 2021, 205(1): 86-93.
|
24. |
McConnell MJ, Actis L, Pachón J. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev, 2013, 37(2): 130-155.
|
25. |
Alfano M, Canducci F, Nebuloni M, et al. The interplay of extracellular matrix and microbiome in urothelial bladder cancer. Nat Rev Urol, 2016, 13(2): 77-90.
|
26. |
Wolfe AJ, Toh E, Shibata N, et al. Evidence of uncultivated bacteria in the adult female bladder. J Clin Microbiol, 2012, 50(4): 1376-1383.
|
27. |
Fujita N, Hatakeyama S, Momota M, et al. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer. Urol Oncol, 2020, 38(8): 684. e17-684. e24.
|
28. |
Sweis RF, Golan S, Barashi N, et al. The commensal urinary microbiome as a predictor of response to Bacillus Calmette-Guerin (BCG) immunotherapy in non-muscle invasive bladder cancer. J Clin Oncol, 2019, 13(79): 423.
|
29. |
Seow SW, Rahmat JN, Bay BH, et al. Expression of chemokine/cytokine genes and immune cell recruitment following the instillation of Mycobacterium bovis, bacillus Calmette-Guérin or Lactobacillus rhamnosus strain GG in the healthy murine bladder. Immunology, 2008, 124(3): 419-427.
|
30. |
Seow SW, Cai S, Rahmat JN, et al. Lactobacillus rhamnosus GG induces tumor regression in mice bearing orthotopic bladder tumors. Cancer Sci, 2010, 101(3): 751-758.
|